Biologics: Target-specific treatment of systemic and cutaneous autoimmune diseases

Indian Journal of Dermatology

Volumn 54, Issue 2, 2009, Pages 100-109

  Raychaudhuri, Siba ^a   Raychaudhuri, Smriti ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NONE

Author keywords

Anti cytokines; B Lymphocyte; Biologics; Immunonodulation; TCR

Indexed keywords

ABATACEPT; ADALIMUMAB; ALEFACEPT; AMG 714; ATACICEPT; ATLIZUMAB; AZATHIOPRINE; BELIMUMAB; CD28 ANTIGEN; CYCLOPHOSPHAMIDE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DISEASE MODIFYING ANTIRHEUMATIC DRUG; EFALIZUMAB; ETANERCEPT; F5 255734; FR 255734; GLUCOCORTICOID; GOLIMUMAB; HYBRID PROTEIN; IMMUNOMODULATING AGENT; INFLIXIMAB; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; METHOTREXATE; MONOCLONAL ANTIBODY CD28; OFATUMUMAB; PLACEBO; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANKYLOSING SPONDYLITIS; AUTOIMMUNE DISEASE; B LYMPHOCYTE; CLINICAL TRIAL; CROHN DISEASE; DEMYELINATING DISEASE; DERMATOMYOSITIS; DISEASE SEVERITY; DRUG ACTIVITY; DRUG APPROVAL; DRUG BINDING; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; DRUG TOLERABILITY; DRUG WITHDRAWAL; HEART FAILURE; HISTOPLASMOSIS; HUMAN; IMMUNE SYSTEM; INFECTION; INJECTION SITE REACTION; LISTERIOSIS; LUPUS VULGARIS; MEMORY T LYMPHOCYTE; MULTIPLE CYCLE TREATMENT; MULTIPLE SCLEROSIS; MYCOSIS; NEUTROPENIA; NONHUMAN; PEMPHIGUS; PEMPHIGUS VULGARIS; PHOTOTHERAPY; PROTEIN TARGETING; PSORIASIS; PSORIASIS VULGARIS; PSORIATIC ARTHRITIS; RECOMMENDED DRUG DOSE; RECTUM CANCER; REVIEW; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; SINGLE DRUG DOSE; SKIN DISEASE; SYSTEMIC DISEASE; SYSTEMIC LUPUS ERYTHEMATOSUS; TH1 CELL; TUBERCULOSIS; ULCERATIVE COLITIS; VASCULITIS;

EID: 68049132899     PISSN: 00195154     EISSN: 19983611     Source Type: Journal    
DOI: 10.4103/0019-5154.53175     Document Type: Review

References (58)

1. Feldmann M, Steinman L. Design of effective immunotherapy for human autoimmunity. Nature 2005;435:612-9.
2. Feldmann M, Brennan FM, Maini R. Cytokines in autoimmune disorders. Int Rev Immunol 1998;17:217-28.
3. Beutler B, Cerami A. The biology of cachectin/TNF: A primary mediator of the host response. Annu Rev Immunol 1989;7:625-55.
4. Locksley RM, Killeen N, Lenardo MJ. The TNF and TNF receptor superfamilies: Integrating mammalian biology. Cell 2001;104:487-501.
5. Zhang G. Tumor necrosis factor family ligand-receptor binding. Curr Opin Struct Biol 2004;14:154.
6. Clark IA. How TNF was recognized as a key mechanism of disease. Cytokine Growth Factor Rev 2007;18:335-43.
7. Hochberg MC, Lebwohl MG, Plevy SE, Hobbs KF, Yocum DE. The benefit/risk profile of TNF-blocking agents: Findings of a consensus panel. Semin Arthritis Rheum 2005;34:819-36.
8. Tak PP, Taylor PC, Breedveld FC, Smeets TJ, Daha MR, Kluin PM, et al. Decrease in cellularity and expression of adhesion molecules by anti-tumor necrosis factor alpha monoclonal antibody treatment in patients with rheumatoid arthritis. Arthritis Rheum 1996;39:1077-81.
9. Taylor PC, Steuer A, Gruber J, McClinton C, Cosgrove DO, Blomley MJ, et al. Ultrasonographic and radiographic results from a two-year controlled trial of immediate or one-year-delayed addition of infliximab to ongoing methotrexate therapy in patients with erosive early rheumatoid arthritis. Arthritis Rheum 2006;54:47-53.
10. Finckh A, Simard JF, Duryea J, Liang MH, Huang J, Daneel S, et al. The effectiveness of anti-tumor necrosis factor therapy in preventing progressive radiographic joint damage in rheumatoid arthritis: A population-based study. Arthritis Rheum 2006;54:54-9.
11. Chaudhari U, Romano P, Mulcahy LD, Dooley LT, Baker DG, Gottlieb AB. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: A randomised trial. Lancet 2001;357:1842-7.
12. Gordon KB, Langley RG, Leonardi C, Toth D, Menter MA, Kang S, et al. Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: Double-blind, randomized controlled trial and open-label extension study. J Am Acad Dermatol 2006;55:598-606.
13. Leonardi CL, Powers JL, Matheson RT, Goffe BS, Zitnik R, Wang A, et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med 2003;349:2014-22.
14. Gottlieb AB, Evans R, Li S, Dooley LT, Guzzo CA, Baker D, et al. Infliximab induction therapy for patients with severe plaque-type psoriasis: A randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol 2004;51:534-42.
15. Jacobi A, Mahler V, Schuler G, Hertl M. Treatment of inflammatory dermatoses by tumour necrosis factor antagonists. J Eur Acad Dermatol Venereol 2006;20:1171-87.
16. Day R. Adverse reactions to TNF-alpha inhibitors in rheumatoid arthritis. Lancet 2002;359:540-1.
17. Donahue KE, Gartlehner G, Jonas DE, Lux LJ, Thieda P, Jonas BL, et al. Systematic review: Comparative effectiveness and harms of disease-modifying medications for rheumatoid arthritis. Ann Intern Med 2008;148:124-34.
18. Genovese MC, Cohen S, Moreland L, Lium D, Robbins S, Newmark R, et al. Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate. Arthritis Rheumat 2004;50:1412-9.
19. Hirano T. Interleukin 6 and its receptor: Ten years later. Int Rev Immunol 1998;16:249.
20. Nishimoto N, Yoshizaki K, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, et al. Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: A multicenter, double-blind, placebocontrolled trial. Arthritis Rheumat 2004;50:1761-9.
21. McInnes I, Martin R, Zimmerman-Gorska I, Nayiager S, Sun G, Patel A, et al. Safety and efficacy of a human monoclonal antibody to IL-15 (AMG 714) in patients with rheumatoid arthritis (RA): Results from a multicenter, randomized, doubleblind, placebo-controlled trial. Arthritis Rheumat 2004;50:527.
22. McInnes IB, Gracie JA. Interleukin-15: A new cytokine target for the treatment of inflammatory diseases. Curr Opin Pharmacol 2004;4:392-7.
23. Asadullah K, Döcke WD, Sabat RV, Volk HD, Sterry W. The treatment of psoriasis with IL-10: Rationale and review of the first clinical trials. Expert Opin Investig Drugs 2000;9:95-102.
24. Siegmund B, Fantuzzi G, Rieder F, Gamboni-Robertson F, Lehr HA, Hartmann G, et al. Neutralization of interleukin-18 reduces severity in murine colitis and intestinal IFN-gamma and TNF-alpha production. Am J Physiol Regul Integr Comp Physiol 2001;281:R1264-73.
25. Holmes S, Abrahamson JA, Al-Mahdi N, Abdel-Meguid SS, Ho YS. Characterization of the in vitro and in vivo activity of monoclonal antibodies to human IL-18. Hybridoma 2000;19:363.
26. Mueller DL, Jenkins MK, Schwartz RH. Clonal expansion versus functional inactivation: A costimulatory signaling pathway determines the outcome of T cell antigen receptor occupancy. Annu Rev Immunol 1989;7:445-80.
27. Linsley PS, Brady W, Grosmaire L, Aruffo A, Damle NK, Ledbetter JA. Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin 2 mRNA accumulation. J Exp Med 1991;173:721-30.
28. Lenschow DJ, Zeng Y, Thistlethwaite JR, Montag A, Brady W, Gibson MG, et al. Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA4Ig. Science 1992;257:789-92.
29. Abrams JR, Lebwohl MG, Guzzo CA, Jegasothy BV, Goldfarb MT, Goffe BS, et al. CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris. J Clin Invest 1999;103:1243-52.
30. Kremer JM, Westhovens R, Leon M, Di Giorgio E, Alten R, Steinfeld S, et al. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med 2003;349:1907-15.
31. Shiao SL, McNiff JM, Masunaga T, Tamura K, Kubo K, Pober JS. Immunomodulatory properties of FK734, a humanized anti-CD28 monoclonal antibody with agonistic and antagonistic activities. Transplantation 2007;83:304-13.
32. Raychaudhuri SP, Kundu-Raychaudhuri S, Tamura K, Masunaga T, Kubo K, Hanaoka K, et al. FR255734, a Humanized, Fc-Silent, Anti-CD28 Antibody, Improves Psoriasis in the SCID Mouse-Psoriasis Xenograft Model. J Invest Dermatol 2008;128:1969-76.
33. Krueger GG, Ellis CN. Alefacept therapy produces remission for patients with chronic plaque psoriasis. Br J Dermatol 2003;148:784-8.
34. Azam P, Sankaranarayanan A, Homerick D, Griffey S, Wulff H. Targeting effector memory T cells with the small molecule Kv1.3 blocker PAP-1 suppresses allergic contact dermatitis. J Invest Dermatol 2007;127:1419-29.
35. Shlomchik MJ, Madaio MP, Ni D, Trounstein M, Huszar D. The role of B cells in lpr/lpr-induced autoimmunity. J Exp Med 1994;180:1295-306.
36. Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, et al. Efficacy of B-Cell-Targeted Therapy With Rituximab in Patients With Rheumatoid Arthritis. N Engl J Med 2004;350:2572.
37. Jónsdóttir T, Gunnarsson I, Risselada A, Henriksson EW, Klareskog L, van Vollenhoven RF. Treatment of refractory SLE with rituximab plus cyclophosphamide: Clinical effects, serological changes, and predictors of response. Ann Rheum Dis 2008;67:330-4.
38. Ahmed AR, Spigelman Z, Cavacini LA, Posner MR. Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin. N Engl J Med 2006;355:1772-9.
39. Miotla J, Maciewicz R, Kendrew J, Feldmann M, Paleolog E. Treatment with soluble VEGF receptor reduces disease severity in murine collagen-induced arthritis. Lab Invest 2000;80:1195-205.
40. Afuwape AO, Feldmann M, Paleolog EM. Adenoviral delivery of soluble VEGF receptor 1 (sFlt-1) abrogates disease activity in murine collagen-induced arthritis. Gene Ther 2003,10:1950-60.
41. Autiero M, Luttun A, Tjwa M, Carmeliet P. Placental growth factor and its receptor, vascular endothelial growth factor receptor-1: Novel targets for stimulation of ischemic tissue revascularization and inhibition of angiogenic and inflammatory disorders. J Thromb Haemost 2003,1:1356-70.
42. Tjwa M, Luttun A, Autiero M, Carmeliet P. VEGF and PlGF: Two pleiotropic growth factors with distinct roles in development and homeostasis. Cell Tissue Res 2003;314:5-14.
43. Autiero M, Waltenberger J, Communi D, Kranz A, Moons L, Lambrechts D, et al. Role of PlGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1. Nat Med 2003;9:936-43.
44. Oosthuyse B, Moons L, Storkebaum E, Beck H, Nuyens D, Brusselmans K, et al. Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degeneration. Nat Genet 2001;28:131-8.
45. Bottomley MJ, Webb NJ, Watson CJ, Holt L, Bukhari M, Denton J, et al. Placenta growth factor (PlGF) induces vascular endothelial growth factor (VEGF) secretion from mononuclear cells and is co-expressed with VEGF insynovial fluid. Clin Exp Immunol 2000;119:182-8.
46. Lebwohl M, Tyring SK, Hamilton TK, Toth D, Glazer S, Tawfik NH, et al. A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N Engl J Med 2003;349:2004-13.
47. Kay J, Matteson EL, Dasgupta N, Nash P, Durez P, Hall S, et al. One-year results of golimumab compared with placebo in patients with active RA despite treatment with methotrexate: A phase II, randomized, double blind, placebo-controlled, dose-ranging trial. Arthritis Rheumat 2006;54:1075.
48. Cua DJ, Sherlock J, Chen Y, Murphy CA, Joyce B, Seymour B, et al. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature 2003;421:744-8.
49. Murphy CA, Langrish CL, Chen Y, Blumenschein W, McClanahan T, Kastelein RA, et al. Divergent pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation. J Exp Med 2003;198:1951-7.
50. Hue S, Ahern P, Buonocore S, Kullberg MC, Cua DJ, McKenzie BS, et al. Interleukin-23 drives innate and T cell-mediated intestinal inflammation. J Exp Med 2006;203:2473-83.
51. Nakee S, Nambu A, Sudo K, Iwakura Y. Suppression of immune induction of collagen -induced arthritis in IL-17 deficient mice. J Immunol 2003;171:6173-7.
52. Lubberts E, Joosten LA, Oppers B, van den Bersselaar L, Coenende Roo CJ, Kolls JK, et al. il-1-independent role of IL-17 in synovial inflammation and joint destruction during collagen -induced arthritis. J Immunol 2001;167:1004-13.
53. Lubberts E, Koenders MI, Oppers-Walgreen B, van den Bresselaar L, Coenen-de Roo CJ, Joosten LA, et al. Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction and bone erosion. Arthritis Rheum 2004;50:650-9.
54. Raychaudhuri SP, Jiang WY, Raychaudhuri SK. Revisiting the Koebner phenomenon: Role of NGF and its receptor system in the pathogenesis of psoriasis. Am J Pathol 2008;172:961-71.
55. Raychaudhuri SP, Sanyal M, Weltman H, Kundu-Raychaudhuri S. K252a, a high-affinity nerve growth factor receptor blocker, improves psoriasis: An in vivo study using the severe combined immunodeficient mouse-human skin model. J Invest Dermatol 2004;122:812-9.
56. Pincelli C, Pignattim M. Keratinocyte-based mechanisms are trendy again in psoriasis-the role of a K252a derivative as a novel treatment. Eur Dermatol Rev 2006;3:13-6.
57. Shelton DL, Zeller J, Ho WH, Pons J, Rosenthal A. Nerve growth factor mediates hyperalgesia and cachexia in autoimmune arthritis. Pain 2005;116:8-16.
58. Lane N, Webster L, Lu S, Gray M, Hefti F, Walicke P. RN624 (Anti- NGF) improves pain and function in subjects with moderate knee osteoarthritis: A phase I study. Arthritis Rheum 2005;52:9.